Armed with fresh trial data, Catabasis doubles down on Duchenne drug
October 04, 2017 at 04:30 AM EDT
The Cambridge biotech said Wednesday that it plans to launch a late-stage study next year, despite an earlier clinical setback that decimated its share price.
